94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Endocrinol.
Sec. Reproduction
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1551126
This article is part of the Research TopicOvarian Aging: Pathophysiology and Recent Development of Maintaining Ovarian Reserve, Volume IVView all 4 articles
The Role of Growth Hormone in Assisted Reproductive Technology for Patients with Diminished Ovarian Reserve: From Signaling Pathways to Clinical Applications
Provisionally accepted- 1Department of Reproductive Medicine, Binzhou Medical University Hospital, Binzhou, China
- 2Linquan County People's Hospital,Fuyang City, Anhui Province, 236400, China., Fuyang, China
- 3Binzhou Medical University, Binzhou, Shandong Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Diminished Ovarian Reserve (DOR) is a complex etiology disease that significantly impacts female fertility, endocrine function, and overall health status. In recent years, the incidence of DOR has been increasing, yet therapeutic methods remain relatively limited, particularly for patients with reproductive needs who often require Assisted Reproductive Technology (ART) treatments. Growth Hormone (GH), a peptide hormone secreted by the anterior pituitary, promotes growth in bones, viscera, and multiple organs and systems throughout the body, enhances protein synthesis, and influences fat and mineral metabolism, playing a crucial role in human growth and development. Its levels decrease with the aging of the organism. In recent years, studies have suggested that a decline in growth hormone levels may be one of the causes of decreased ovarian function, leading to the application of GH in assisted reproductive treatments for patients with DOR .An increasing body of research indicates that GH can improve ovarian function through mechanisms such as antioxidant stress, promotion of follicle development, and enhancement of oocyte quality, and it also shows potential to improve endometrial receptivity, making GH a promising safe and effective strategy in ART for DOR patients.
Keywords: diminished ovarian reserve, Growth Hormone, Oxidative Stress, signaling pathway, Reactive Oxygen Species
Received: 24 Dec 2024; Accepted: 31 Mar 2025.
Copyright: © 2025 Han, Xu, Yuan, Wen, Yang, Han and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Lei Han, Department of Reproductive Medicine, Binzhou Medical University Hospital, Binzhou, China
Dongmei Zhang, Department of Reproductive Medicine, Binzhou Medical University Hospital, Binzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.